Blog

How Do You Gauge the Success of a Marketing Investment in Cycling? (Part 3)

Finally, how can we analyze the impact of a cycling sponsorship on our brand and visibility?  The answer is “indirectly.” First, we see upticks in activity on social media when we directly engage our followers with specific news about the cycling team.  Tweets are retweeted, views of LinkedIn posts tick up.   Back Bay Cycling Club and Ride Studio Cafe helped us promote the launch of the team with a party last summer, and this got good social media buzz.  Because most …

Continue reading

How Do You Gauge the Success of a Marketing Investment in Cycling? (Part 2)

Companies that sponsored cycling teams in the past thought of their investments as “rolling billboards.”  Particularly for the road racing disciplines, cyclists would wear their logo-covered jerseys and shorts in training and commuting as well as while racing, in theory increasing the likelihood that a customer – even one not interested  in biking – would recognize the logo when seeing it in another context.  Marketing people speak of “touches” – maximizing the tiny, maybe even subliminal, engagements of your brand …

Continue reading

How Do You Gauge the Success of a Marketing Investment in Cycling?

Averica made a decision in 2014 to apply effort and investment to “inbound marketing,” the art of helping potential customers find us.  Inbound marketing recognizes that today consumers search for a provider instead of the vendor pitching to customers.  Think how door-to-door sales changed to cold calling, and changed again – now we research products and companies on the web and place orders directly online, with no human interaction in the sale at all. Inbound marketing requires that the potential …

Continue reading

EPSA: A New Bioavailability / Permeability Assay

Predictive assays or calculations are established approaches to understanding a drug’s potential bioavailability.  A key physical property to understanding this is polar surface area, sometimes discussed as hydrogen bond availability.  The most common way of evaluating this is to calculate the structure’s Topological Polar Surface Area (TPSA) 1.  While valuable for rank ordering similar molecules, TPSA suffers by not accounting for conformational changes in a molecule in solution and does not account for potential Intramolecular Hydrogen Bonds (IMHB). EPSA, developed …

Continue reading

Discussing Biotech 2.0 at the NE CRO/CMO Council’s Town Hall with Travis McCready

The New England CRO/CMO Council’s town hall meeting with Travis McCready, newly appointed head of the Massachusetts Life Sciences Center (MLSC), and Michael Kennealy, the Assistant Secretary for Business Growth in the office of Housing and Economic Development headed by Secretary Jay Ash, was a success, judging by the attendance and the quality of the conversation among McCready and Kennealy and council members. Executives from approximately 30 companies were able to introduce themselves and their companies to McCready and Kennealy, …

Continue reading

A Better Way To Look At Risk/Reward During Early Drug Development?

How do you add value to a compound while maintaining cost effectiveness?  The answer might depend on whether you’re part of the cautious development team, or hard-driving discovery team.  In Pharmaceutical Online’s article, “Relative Cost Models: A Better Way To Look At Risk/Reward During Early Drug Development?”, guest columnist Jeff Kiplinger considers the role chromatography plays in managing risk as chemists narrow down the number of compounds of interest.   Want to read more articles about value and risk reduction …

Continue reading

BBJ Bioflash – Featuring Push for Growth in MA Life Science Sector

Don Seiffert’s article, published in the BBJ Bioflash Sept 10, 2015, follows the recent ViewPoint piece written by Averica’s Jeff Kiplinger and PCI’s Ed Price.  Kiplinger and Price are co-founders of the New England CRO/CMO Council, a group formed to promote the role contract research and contract manufacturing organizations play in the current pharmaceutical development model. Link to the Article

Continue reading

Mass. Needs to Recognize Biotech Evolution

ViewPoint Article Published in Boston Business Journal (BBJ) By Edward S. Price, President, PCI Synthesis and Jeffrey P. Kiplinger, President, Averica Discovery Services   The biotech sector in Massachusetts has changed – but you might not realize that based on state policies. The Massachusetts Life Sciences Act, signed into law in 2008, provided tax incentives and investment of $1 billion.  The Act capped years of investment in the Boston-centered cluster – the biggest in the world with big pharma/biotech, venture-backed …

Continue reading

5 Keys to Fast Impurity Isolation

Sometimes you know a lot about the genesis of pharmaceutical impurities, and in some cases you know very little.  In either case, here are some things that you can try to make impurity isolation faster and improve the chances of success. Produce an enriched sample Whether from stress degradation, mother liquor, extraction, or chromatography; starting with an enriched sample helps reduce timelines in processing the feedstock for isolation. Know something about the chemical stability – or instability – of the …

Continue reading

The Life of a Chiral Sample

Chiral resolution1 is the process of separating racemic compounds into their enantiomers.  Scientists looking to study one of the isomers choose between chiral chromatography, asymmetric synthesis, or diastereomeric crystallization to supply material2. Averica’s scientists are experts in chromatography.  We find this to be the fastest method for delivering highly pure material.  This video offers a glimpse into our methodology as it chronicles a chiral sample as it travels through our lab. Learn more about Chiral Separation Services from Averica. Wikipedia’s information about …

Continue reading